KVUE - Kenvue Inc. Последние новости | Finranks

16.03.2026

I'm Buying Dividend Aristocrats At Bargain Basement Prices

Medtronic and Kimberly-Clark are Dividend Aristocrats trading well below historical valuations, offering compelling buy-the-dip opportunities. MDT has strong revenue growth, a robust innovation pipeline, and a 3.3% yield, with a forward P/E of 15.4 versus its historical 17.5. KMB is executing on transformation and innovation, with margin gains, a 5.2% yield, and a forward P/E of 13.0, far below its historical 17.7.

06.03.2026

Tylenol use among women dropped after Trump tied it to autism

Tylenol use among pregnant women fell after U.S. President Donald Trump linked autism to the over-the-counter pain relief medicine, according to an analysis of U.S. emergency room prescribing patterns published in the UK medical journal Lancet.

04.03.2026

KVUE vs. PG: Which Stock Is the Better Value Option?

Investors looking for stocks in the Consumer Products - Staples sector might want to consider either Kenvue (KVUE) or Procter & Gamble (PG). But which of these two stocks offers value investors a better bang for their buck right now?

27.02.2026

Best Dividend Aristocrats For March 2026

The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) is up 9.39% YTD in 2026, decisively outperforming SPY's 1.08%. Dividend Aristocrats are regaining momentum after a weak 2025, with 55 outpacing SPY and 39 posting double-digit gains this year already. Dividend growth is lagging, with 2026's average increase currently at 3.22%, below last year's trend and potentially signaling headwinds.

26.02.2026

Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol

A Texas judge on Thursday rejected Kenvue's bid to dismiss a lawsuit by that state's Attorney General Ken Paxton accusing the company of concealing autism and other risks to children when pregnant women use Tylenol.

24.02.2026

20 Years on Wall Street Taught Me: Boomers Feel Safe With 5 High-Yield Dividend Giants

After a 35-year career in the finance industry, including two decades as an institutional stockbroker at Bear Stearns, Lehman Brothers, and Morgan Stanley, I developed an institutional perspective on dividend-focused investing.

18.02.2026

Stock Market Today, Feb. 18: Kenvue Rises After Earnings Beat Expectations

On Feb. 18, 2026, investors weighed Kenvue's earnings momentum against looming merger costs and related risks.

Видео

03.11.2025

Positive

Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger

03.11.2025

Positive

Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
KVUE	Canaccord Genuity	Hold	undefined >> $15	October 29th 2025
KVUE	Rothschild & Co Redburn	Buy	undefined >> $22	September 26th 2025
KVUE	Redburn Atlantic	Neutral	undefined >> $24	April 10th 2025

Пресс-релизы

17.02.2026

Kenvue Reports Fourth Quarter and Full Year 2025 Results

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal fourth quarter and full year ended December 28, 2025. “We ended 2025 with stronger top- and bottom-line performance in the fourth quarter, which reflected both disciplined execution against our strategic priorities, as well as a more favorable year-ago comparison on sales,” said Kirk Perry, Chief Executive Officer. “As we look to 2026, we remain focused on continuing to enhance our performan.

Kenvue Inc. (KVUE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях